Novo Nordisk A/S $NVO Shares Sold by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 12.1% in the 4th quarter, Holdings Channel reports. The firm owned 194,057 shares of the company’s stock after selling 26,640 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Novo Nordisk A/S were worth $9,874,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $25,000. WealthCollab LLC raised its stake in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the last quarter. American National Bank & Trust acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $28,000. Maseco LLP acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $29,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.3%

Shares of NYSE:NVO opened at $42.73 on Thursday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average of $41.98 and a two-hundred day moving average of $46.04. The stock has a market cap of $190.78 billion, a P/E ratio of 10.03, a PEG ratio of 3.78 and a beta of 0.78. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion for the quarter. On average, research analysts expect that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on NVO shares. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a report on Tuesday, March 3rd. Finally, Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $65.56.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported that its Wegovy pill has surpassed 3 million prescriptions, signaling strong early demand for the oral obesity treatment and reinforcing the company’s competitive position versus Eli Lilly in the fast-growing GLP-1 market. Novo Wegovy Pill Tops 3M Prescriptions
• Positive Sentiment: The company also said that more than 80% of Wegovy pill customers have never used a GLP-1 before, which suggests the product is expanding Novo’s addressable market beyond existing obesity-drug users. Novo Nordisk CEO interview on Wegovy pill customers
• Positive Sentiment: Novo Nordisk introduced an updated Rybelsus tablet formulation in Canada, adding a more convenient version of its diabetes GLP-1 drug and supporting the company’s broader cardiometabolic franchise. Novo Nordisk introduces updated Rybelsus tablet formulation in Canada
• Neutral Sentiment: Several articles highlighted Novo Nordisk as a key beneficiary of the GLP-1 boom and as part of healthcare ETF exposure themes, which may keep the stock in focus but do not change fundamentals directly. Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
• Neutral Sentiment: Novo’s CEO reiterated that the company aims to be a “cardiometabolic powerhouse” with a diversified pipeline, reinforcing a long-term growth narrative. Novo Nordisk CEO interview
• Negative Sentiment: Novo Nordisk is also heading to court in South Africa to try to stop sales of unapproved semaglutide copies, underscoring ongoing legal and counterfeit-product risks tied to its blockbuster drugs. Novo Nordisk faces off in court with South African weight-loss drug compounder

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.